ArrayExpress Uploader037760 ug/mlUntreated0A20081 ug/mlA3A20082 ug/mlB3A20083 ug/mlC3A20083 ug/mlA6A20084 ug/mlB6A20085 ug/mlC6A20080 ug/mlUntreated0A2780CP1 ug/mlA3A2780CP2 ug/mlB3A2780CP3 ug/mlC3A2780CP3 ug/mlA6A2780CP4 ug/mlB6A2780CP5 ug/mlC6A2780CP0 ug/mlUntreated0A2780S1 ug/mlA3A2780S2 ug/mlB3A2780S3 ug/mlC3A2780S3 ug/mlA6A2780S4 ug/mlB6A2780S5 ug/mlC6A2780S0 ug/mlUntreated0C131 ug/mlA3C132 ug/mlB3C133 ug/mlC3C133 ug/mlA6C134 ug/mlB6C135 ug/mlC6C130 ug/mlUntreated0IGROV11 ug/mlA3IGROV12 ug/mlB3IGROV13 ug/mlC3IGROV13 ug/mlA6IGROV14 ug/mlB6IGROV15 ug/mlC6IGROV10 ug/mlUntreated0OV20081 ug/mlA3OV20082 ug/mlB3OV20083 ug/mlC3OV20083 ug/mlA6OV20084 ug/mlB6OV20085 ug/mlC6OV20080 ug/mlUntreated0OVCAR51 ug/mlA3OVCAR52 ug/mlB3OVCAR53 ug/mlC3OVCAR53 ug/mlA6OVCAR54 ug/mlB6OVCAR55 ug/mlC6OVCAR50 ug/mlUntreated0T81 ug/mlA3T82 ug/mlB3T83 ug/mlC3T83 ug/mlA6T84 ug/mlB6T85 ug/mlC6T8arrayexpress_sid4We treated 8 human ovarian cancer cell lines with cisplatin in treatment/recovery cycles to induce in-vitro resistance to the drug....21849418E-GEOD-23553/profile/8773/arrayexpressuploader456cancercellgenomelineovarian cancerDec.12, 2014Falsegene-expression-changes-with-induction-of-in-vitroE-GEOD-23553_A-AFFY-44Gene expression changes with induction of in-vitro platinum-resistance in ovarian cancer cell lines.Sep.15, 2014We treated 8 human ovarian cancer cell lines with cisplatin in treatment/recovery cycles to induce in-vitro resistance to the drug. Microarrays measured gene expression at baseline and after each dose schedule (after recovery). OVCA cells lines (T8, OVCAR5, OV2008, IGROV1, C13, A2780S, A2780CP, and A2008) were used in the study. Cells were subject to sequential treatment with increasing doses of cis-diammine-dichloroplatinum (cisplatin, CIS), using three dosing schedules resulting in a total of 144 treatment/expansion cycles. Treatment schedules A, B and C included three treatments with 1, 2 and 3μg/ml CIS respectively, followed by three treatments with 3, 4 and 5μg/ml, respectively. Each CIS-treatment was followed by a cell recovery/expansion phase. Both CIS-resistance and genome-wide expression changes were measured serially in each cell line at baseline and after 3 and 6 CIS-treatment/expansion cycles. CIS-resistance was quantified using CellTiter-96, MTS proliferation assays (Fisher Scientific) and genome-wide expression was performed using Affymetrix Human U133 Plus 2.0 GeneChips as previously described.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-23553humanhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-23553/samples/